GSK lightens portfolio, shrinks footprint

Share this article:
GSK lightens porfolio, shrinks footprint
GSK lightens porfolio, shrinks footprint

GlaxoSmithKline is selling thrombosis meds Arixtra and Fraxiparine to the Aspen Group, a longtime partner in GSK's ongoing effort to transfer drugs from its books to another entity. The company said in a statement Monday that the deal will include $1.3 million in cash and that it transfers global rights, with few exceptions, to the products and to a manufacturing site (the Notre Dame de Bondeville site) and “certain dedicated commercial employees.” GSK said in a statement that the deal “is a further example of GSK's commitment to increase focus on products with the most growth potential.”

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions